Endpoint Health, an AI-powered precision medicine platform designed to improve the clinical decision-making outcomes of illnesses like sepsis, acute respiratory distress syndrome (ARDS), and COVID-19, received $12 million in funding.
Investors include Mayfield, Y Combinator, AME Cloud Ventures, and Wireframe Ventures.
The company, led by the experienced executive team, including the co-founders of GeneWEAVE, an infection detection and therapy guidance company that was acquired by Roche in 2015 for $425 million, is also collaborating with over 40 top U.S. and international hospitals to bring targeted therapies to critically ill patients.
Endpoint Health is building a precision medicine platform focused on critical illness and complex diseases. The platform also helps to develop targeted therapies as well as validate targeted therapies for patients suffering from rear diseases.
With new funds, the company plans to bring personalized life-saving targeted therapies to each patient.
“Critical illnesses make up half of U.S. hospital mortality and over $100 billion of our annual healthcare spend. Sepsis alone is associated with as many global deaths as cancer each year, and yet patients with these life-threatening illnesses still have few treatment options,” said Jason Springs, co-founder, and CEO of Endpoint Health. “The COVID-19 pandemic, which placed unprecedented numbers of patients in the ICU, has drawn the world’s attention to the desperate need for advances in this field. We need a new approach to how we understand these illnesses and how we develop and deliver treatments.”
Precision medicine companies raised over $1 billion since 2012, according to Mercom database. Recently, Tempus, a precision medicine company, raised $100 million in a Series G financing round at a $5 billion post-money valuation. Investors include Baillie Gifford, Franklin Templeton, New Enterprise Associates (NEA), Novo Holdings, and funds and accounts managed by T. Rowe Price.
Clinical Decision Support companies raised $545 million in 1H 2020. The funding activity was up in 1H 2020 by 90%, compared to $287 million raised in 1H 2019.
